FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2903879969> ?p ?o ?g. }

• W2903879969 endingPage "3009" @default.
• W2903879969 startingPage "3009" @default.
• W2903879969 abstract "Abstract Background: In chronic myeloid leukemia (CML), deep molecular responses improve long-term prognosis, and patients (pt) with sustained MR4.5 are candidates for treatment discontinuation. Hence, eliminating minimal residual disease (MRD) in CML is an important goal of tyrosine kinase inhibitor (TKI) therapy. JAK-STAT signaling is constitutively activated in CML. Preclinical studies have shown JAK2 inhibition to induce apoptosis of CML stem cells. Ruxolitinib (RUX) is a potent, selective inhibitor of JAK1/2 which has shown activity in myeloproliferative neoplasms. We hypothesized that adding ruxolitinib to ongoing TKI therapy may improve the depth of response. Methods: This was a phase I/II open label single center study. We enrolled pts ≥18 yrs with BCR/ABL-positive CML on continuous imatinib (IM) therapy for at least 18 months (mo) and stable dose for 6 mo with complete cytogenetic response (CCyR). Pts needed to have detectable BCR-ABL transcripts by polymerase chain reaction (PCR), either had never achieved major molecular response (MMR), or lost MMR with 1-log fold rise in PCR, or lacked sustained MMR despite ≥2 years of TKI therapy, or lacked sustained (≥2 years) complete molecular response (CMR, defined as undetectable BCR-ABL PCR with at least 100,000 abl copies detected) despite ≥5 years on TKI. BCR-ABL transcripts were tested using quantitative real-time reverse-transcriptase PCR. Pts needed to have ECOG score ≤2 and adequate organ function. For the phase I portion, pts only needed to be in complete hematologic response, only pts on IM were eligible and those with history of blast phase (BP) were excluded. Dose escalation was done using a 3+3 design. Pts could continue therapy with RUX for up to 3 years. The primary objectives were to determine dose-limiting toxicities (DLT) and maximum tolerated dose (MTD) of the combination of IM and RUX, and to determine the clinical activity of the combination. Secondary objectives were to determine safety of the combination, rates of one-log reduction of BCR-ABL PCR from baseline or CMR, and survival outcomes including overall survival (OS), event-free survival (EFS), and survival free from blastic transformation. Results: Between November 2013 and July 2018 we enrolled 8 pts in the phase I portion of the study. The pt characteristics are shown in table 1. 1 pt did not have sustained CMR and the other 7 pts had increasing PCR which prompted enrollment. The median baseline BCR-ABL at enrollment was 0.0473 IS (range 0.0032-1). 1 pt is too early for assessment. The remaining 7 pts had been followed-up for a median of 46.6 mo (range 9.5-57.1) and had received RUX for a median of 12.4 mo (range 4.6-37.1). RUX dosing was 5 mg BID (dose level 0), 10 mg BID (dose level 1) and 15 mg BID (dose level 2) for 3, 3 and 2 pts, respectively. The median PCR at the end of study was 0.07 IS (range undetectable-3.4895, fig. 1) There were no DLTs. The MTD of RUX in combination with IM is 15 mg twice daily. There have been 39 treatment-emergent adverse events (TEAEs) in 6 pts with 10 grade 3/4 TEAEs. The most common TEAEs were infections (23%) and anemia (8%). The infections comprised 3 cases of pneumonia (unknown pathogen), 2 cases of upper respiratory tract infection, 1 case of E. coli sepsis, 1 case of shingles, and 1 case of gastroenteritis. There was 1 grade 5 TEAE of cardiac arrest unrelated to the study regimen. There were 10 unique serious AEs in 4 pts, all unrelated to study drug. 1 pt who started treatment with MR4.5 achieved intermittent CMR 18 mo into therapy. 1 pt who started treatment with PCyR after being on 2nd line TKI for 21.6 mo achieved CCyR 6 mo into therapy. No pt achieved the other response criteria of 1-log fold BCR-ABL reduction (fig. 1). No pt progressed to BP. Median OS and EFS has not been reached (NR, range 52.7 mo-NR). 7 pts have discontinued and 1 pt was recently started on therapy. Reasons for treatment discontinuation include completion of therapy in 2 pts, lack of response in 2 pts, withdrawal of consent in 2 pts, and death in 1 pt (due to cardiac arrest unrelated to study regimen). The pt who died had never achieved CCyR despite 28.5 mo on TKI and had never achieved MMR. Conclusion: It is feasible to combine RUX with IM for pts with persistent minimal residual CML while receiving TKI. There were no DLTs with RUX 15 mg BID and IM. However, in this small cohort of pts, the combination of RUX and IM did not have any significant effect on reducing MRD. The trial is being amended to include pts receiving other TKI. Disclosures Maiti: Celgene Corporation: Other: Research funding to the institution. Jabbour:Novartis: Research Funding; Takeda: Consultancy, Research Funding; Abbvie: Research Funding; Pfizer: Consultancy, Research Funding; Bristol-Myers Squibb: Consultancy, Research Funding. Ravandi:Jazz: Honoraria; Bristol-Myers Squibb: Research Funding; Bristol-Myers Squibb: Research Funding; Xencor: Research Funding; Sunesis: Honoraria; Sunesis: Honoraria; Orsenix: Honoraria; Amgen: Honoraria, Research Funding, Speakers Bureau; Seattle Genetics: Research Funding; Astellas Pharmaceuticals: Consultancy, Honoraria; Macrogenix: Honoraria, Research Funding; Orsenix: Honoraria; Astellas Pharmaceuticals: Consultancy, Honoraria; Abbvie: Research Funding; Macrogenix: Honoraria, Research Funding; Xencor: Research Funding; Amgen: Honoraria, Research Funding, Speakers Bureau; Abbvie: Research Funding; Seattle Genetics: Research Funding; Jazz: Honoraria. Cortes:Pfizer: Consultancy, Research Funding; Daiichi Sankyo: Consultancy, Research Funding; Arog: Research Funding; Astellas Pharma: Consultancy, Research Funding; Novartis: Consultancy, Research Funding." @default.
• W2903879969 created "2018-12-22" @default.
• W2903879969 creator A5000750846 @default.
• W2903879969 creator A5007472573 @default.
• W2903879969 creator A5015101485 @default.
• W2903879969 creator A5015764176 @default.
• W2903879969 creator A5040932734 @default.
• W2903879969 creator A5049385583 @default.
• W2903879969 creator A5075581944 @default.
• W2903879969 creator A5084379902 @default.
• W2903879969 date "2018-11-29" @default.
• W2903879969 modified "2023-10-15" @default.
• W2903879969 title "Phase I/II Study of Ruxolitinib for Minimal Residual Disease in Chronic Myeloid Leukemia" @default.
• W2903879969 doi "https://doi.org/10.1182/blood-2018-99-113972" @default.
• W2903879969 hasPublicationYear "2018" @default.
• W2903879969 type Work @default.
• W2903879969 sameAs 2903879969 @default.
• W2903879969 citedByCount "0" @default.
• W2903879969 crossrefType "journal-article" @default.
• W2903879969 hasAuthorship W2903879969A5000750846 @default.
• W2903879969 hasAuthorship W2903879969A5007472573 @default.
• W2903879969 hasAuthorship W2903879969A5015101485 @default.
• W2903879969 hasAuthorship W2903879969A5015764176 @default.
• W2903879969 hasAuthorship W2903879969A5040932734 @default.
• W2903879969 hasAuthorship W2903879969A5049385583 @default.
• W2903879969 hasAuthorship W2903879969A5075581944 @default.
• W2903879969 hasAuthorship W2903879969A5084379902 @default.
• W2903879969 hasConcept C126322002 @default.
• W2903879969 hasConcept C143998085 @default.
• W2903879969 hasConcept C203014093 @default.
• W2903879969 hasConcept C2776112149 @default.
• W2903879969 hasConcept C2777413986 @default.
• W2903879969 hasConcept C2777583451 @default.
• W2903879969 hasConcept C2778461978 @default.
• W2903879969 hasConcept C2778715236 @default.
• W2903879969 hasConcept C2778729363 @default.
• W2903879969 hasConcept C2779823535 @default.
• W2903879969 hasConcept C2780007613 @default.
• W2903879969 hasConcept C2780076729 @default.
• W2903879969 hasConcept C3019892230 @default.
• W2903879969 hasConcept C502942594 @default.
• W2903879969 hasConcept C71924100 @default.
• W2903879969 hasConceptScore W2903879969C126322002 @default.
• W2903879969 hasConceptScore W2903879969C143998085 @default.
• W2903879969 hasConceptScore W2903879969C203014093 @default.
• W2903879969 hasConceptScore W2903879969C2776112149 @default.
• W2903879969 hasConceptScore W2903879969C2777413986 @default.
• W2903879969 hasConceptScore W2903879969C2777583451 @default.
• W2903879969 hasConceptScore W2903879969C2778461978 @default.
• W2903879969 hasConceptScore W2903879969C2778715236 @default.
• W2903879969 hasConceptScore W2903879969C2778729363 @default.
• W2903879969 hasConceptScore W2903879969C2779823535 @default.
• W2903879969 hasConceptScore W2903879969C2780007613 @default.
• W2903879969 hasConceptScore W2903879969C2780076729 @default.
• W2903879969 hasConceptScore W2903879969C3019892230 @default.
• W2903879969 hasConceptScore W2903879969C502942594 @default.
• W2903879969 hasConceptScore W2903879969C71924100 @default.
• W2903879969 hasIssue "Supplement 1" @default.
• W2903879969 hasLocation W29038799691 @default.
• W2903879969 hasOpenAccess W2903879969 @default.
• W2903879969 hasPrimaryLocation W29038799691 @default.
• W2903879969 hasRelatedWork W2061493553 @default.
• W2903879969 hasRelatedWork W2088660297 @default.
• W2903879969 hasRelatedWork W2133160557 @default.
• W2903879969 hasRelatedWork W2484136943 @default.
• W2903879969 hasRelatedWork W2528188718 @default.
• W2903879969 hasRelatedWork W2896643643 @default.
• W2903879969 hasRelatedWork W2898460622 @default.
• W2903879969 hasRelatedWork W2953080307 @default.
• W2903879969 hasRelatedWork W2989453757 @default.
• W2903879969 hasRelatedWork W3208584668 @default.
• W2903879969 hasVolume "132" @default.
• W2903879969 isParatext "false" @default.
• W2903879969 isRetracted "false" @default.
• W2903879969 magId "2903879969" @default.
• W2903879969 workType "article" @default.